CClinicalTrials.gg
CompletedNCT06659861Updated Mar 17, 2025

Efficacy of Cosmetic Product RV3278B-OS0386 on Skin Surface Ecosystem, in Teenagers with Mild to Moderate Facial Acne

An interventional study of RV3278B-OS0386 and RV4632A-RY1845 in Acne, sponsored by Pierre Fabre Dermo Cosmetique. Completed at 1 site in Romania. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Pierre Fabre Dermo Cosmetique · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

The aim of this exploratory study is to better understand the mechanisms of action of the RV3278B-OS0386 cosmetic product on the cutaneous ecosystem, in acne context.

Read the detailed description

This study will be conducted as an exploratory monocentric, randomized, comparative study.

A total number of 52 subjects (teenagers with mild to moderate facial acne) will be included and randomized in two parallel groups :

  • The tested group who will apply the tested product RV3278B-OS0386
  • The control group who will not apply the tested product. However, they will receive the associated product (RV4632A-RY1845), to be applied in the event of facial skin discomfort only.

    3 visits are planned:

    • Visit 1 (Day 1) : Inclusion, randomization, collection of biological samples on the forehead and start of product application.
    • Visit 2 (Day 29 +/- 3 days) : Phone call follow-up
    • Visit 3 (Day 57, a window of + 3 days is allowed): End-of-study visit - Collection of biological samples on the forehead.
02

Conditions studied

  • Acne

Browse trials for

Keywords

  • Skin ecosystem
  • cosmetic care product
03

In context

Acne Vulgaris

730 studies on the registry are indexed under Acne Vulgaris; 86 are open to participants now.

This study's enrollment of 52 is below the median of 69 across 628 interventional studies indexed under Acne Vulgaris.

Browse Acne Vulgaris studies →

Lead sponsor

Pierre Fabre Dermo Cosmetique is the lead sponsor of 58 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Criteria related to the population:

  • Female and male aged between 12 and 17 years included
  • Subject having signed his/her written informed consent/assent for his/her participation in the study
  • Subject whose parent(s) or guardian(s) has (have) given his/her (their) written consent for their child's participation in the study
  • Subject affiliated to a social security system or health insurance, or is a beneficiary
  • Subject whose parent(s) or guardian(s) is (are) registered with health social security or health insurance
  • Subject and/or parents certifying the truth of the personal information declared to the investigator
  • Cooperative subject and/or parent(s)/legal representative(s), aware of the necessity and duration of controls so that perfect adhesion to the protocol established by the clinical trial centre could be expected
  • Subject with phototype I, II, III, IV according to the Fitzpatrick scale
  • For woman/girl of childbearing potential:

    • use of an effective method of contraception, as assessed by the investigator, introduced and unchanged for at least 1 month (3 months in case of hormonal contraception) before inclusion in the study
    • accept to go on using it during the whole duration of the study

Criteria related to the skin condition (acne):

  • Subject with combination, combination to greasy skin tendency or oily skin on face
  • Subject with mild to moderate acne vulgaris on face; GEA from 2 to 3
  • Subject with predominantly non-inflammatory acne on the forehead
  • Subject with at least 20 open comedones on the face, excluding the nose area, at the inclusion

Subject presenting on his/her forehead (extension possible to the temples, but excluding the hair): target areas suitable for study samplings and measurements:

Inclusion criteria required for at least 26 subjects:

  • Subject having a sensitive skin, according to his/her own self-assessment

Criteria related to the treatments and/or products:

  • Subject who used the same facial cleansing product, shaving products, make-up (if applicable) for at least 1 month before inclusion and is willing to keep it during the whole duration of the study

Non Inclusion Criteria:

Criteria related to the population:

  • Subject unable to understand the information given including study procedures (for linguistic or psychiatric reasons) and to give his/her consent in writing and to report required information in writing in his/her diary
  • Subject whose parent(s) or guardian(s) is(are) unable to understand the information given (for linguistic or psychiatric reasons) and to give his/her consent in writing
  • For woman of childbearing potential: pregnant or breastfeeding or planning to be pregnant during the study
  • Subject who has forfeited his/her freedom by administrative or legal award or is under guardianship
  • Subject whose parent(s) or guardian(s) who has forfeited his/her freedom by administrative or legal decision or under guardianship
  • Subject or parent(s)/legal representative(s) not able to be contacted in case of emergency
  • Subject who, in the judgement of the investigator, is not likely to be compliant with study-related constraints and requirements
  • Subject whose parent(s) or guardian(s) is(are) unable to comply with study-related constraints
  • Subject admitted in a sanitary or social facility
  • Subject planning an hospitalization during the study
  • Subject who is currently participating, who plans to participate or who has participated within the previous weeks or months in another clinical study liable to interfere with the study assessments according to the investigator's assessment
  • Subject is in a position likely to represent a conflict of interest and/or is a family member of any people involved in the conduct of the study (secretary, nurse, technician,...), of the investigational site

Criteria related to the subject's health / skin condition:

  • Subject with history of allergy or intolerance to any of the study products ingredients
  • Subject with history of allergy or intolerance to any material used for the research (like pen, pencil, marker pen, sticking plaster...)
  • Subject having any other dermatologic condition than acne, or characteristics (like tattoo) on the study area(s) liable to interfere with the study assessments
  • Subject having a dermatological condition, an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
  • Presence of more than an acne inflammatory nodule in the whole face
  • Clinical signs of hormone dysfunction or hyperandrogenism
  • Severe form of acne (acne conglobate, acne fulminans or nodulocystic acne) or acneiform eruptions, in the investigator's opinion
  • Exposure to UV-Rays or excessive exposure to sunlight within the previous month

Criteria related to treatments and/or products:

  • Any surgery, chemical (e.g.: skin peel) or physical treatment on the face in the 12 months before the inclusion visit or planned during the study
  • Systemic isotretinoin treatment taken in 6 months before the inclusion or planned during the study
  • Systemic acne treatment (e.g., zinc gluconate, antibiotics, hormonal treatment [excluding contraception] ...] taken in the 3 months before the inclusion or planned to be taken during the study
  • Probiotics taken orally in the month before the inclusion or planned to be taken during the study
  • Use of self-tanning product on the face in the month before the inclusion or planned to be used during the study
  • Topical acne treatment (e.g., benzoyl peroxide, vitamin A and its derivates) applied on the face in the month before the inclusion or planned during the study
  • Topical or systemic Non-Steroidal Anti-Inflammatory (NSAI), corticosteroids, taken or applied to the face in the 2 weeks before the inclusion or planned to be taken/applied during the study
  • Change in subject's usual make-up, facial hygiene habits, cleansing products, care products, shaving products and/or use new products on the face in the 2 weeks before the inclusion visit or planned during the study
  • Skincare product for acne (e.g., product containing any ingredient, like "anti-blemish" active ingredient, liable to interfere with the study according to investigator's assessment) applied to the face in the 2 weeks before the inclusion visit or planned to be applied during the study
  • Home care on the face (including exfoliation, masks, home peels, etc.) used in the 2 weeks before the inclusion visit or planned to be used during the study
  • Any topical or systemic treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the assessments performed during the study according to the investigator's opinion
  • Last face shaving performed in the 2 days before the inclusion visit
  • Any topical treatment or product (including make-up) applied to the face between the last wash (performed the day before the visit) and the inclusion visit
  • Water applied on the face within 8 hours before the inclusion
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Test Group

    This group will apply the RV3278B-OS0386 cosmetic product for acne prone skin.

    Other: RV3278B-OS0386

  • Other
    Control Group

    This group will receive the associated cosmetic product RV4632A-RY1845 (emollient cream), to be applied in the event of facial skin discomfort only.

    Other: RV4632A-RY1845

Interventions

  • OtherRV3278B-OS0386

    Cosmetic product to be applied twice a day on the face during the whole study

  • OtherRV4632A-RY1845

    Cosmetic product to be applied in the event of facial skin discomfort only

06

What researchers measure

Primary outcomes

  1. Effect of the RV3278B on acne severity

    Assessed by the investigator on a 6-point scale (0 to 5 with 0: clear and 5: very severe)

    Time frame: Change from Visit 1 (Day 1) to Visit 3 (Day 57).

  2. Effect of the RV3278B on open comedones.

    Quantification of open comedones

    Time frame: Change from Visit 1 (Day 1) to Visit 3 (Day 57).

  3. Effect of the RV3278B on biological criteria within isolated comedones

    Analyses of comedone composition

    Time frame: Change from Visit 1 (Day 1) to Visit 3 (Day 57).

  4. Effect of the RV3278B on biological criteria from the skin surface

    Analyses of skin microbiota

    Time frame: Change from Visit 1 (Day 1) to Visit 3 (Day 57).

  5. Effect of the RV3278B on biometrological criteria

    Skin potential hydrogen measurement by pH meter

    Time frame: Change from Visit 1 (Day 1) to Visit 3 (Day 57).

  6. Adverse events related to RV3278B

    Adverse events occurrence will be determined by the subject's/parent(s) or guardian(s) spontaneous reporting, the investigator's non-leading questioning and his/her clinical evaluation

    Time frame: From Visit 1 (Day 1) to Visit 3 (Day 57)

Secondary outcomes

  1. Illustrative Outcome : Standardized photographs of the subject's face

    Time frame: Visit 1 (Day 1) to Visit 3 (Day 57).

07

Study locations

1 site
  • Cidp Romania
    Bucharest, 011607, Romania
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06659861
Lead sponsor
Pierre Fabre Dermo Cosmetique
Responsible party
Sponsor
First posted
Oct 26, 2024
Start date
Oct 10, 2024
Primary completion
Mar 6, 2025
Completion
Mar 6, 2025
Last update
Mar 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion